On May 16 in New York, Endpoints News and the Financial Times are teaming up to host the US Pharma and Biotech Summit.
I’ve been deeply involved in planning our interviews and panels, and we have a fantastic program about artificial intelligence, different approaches to the US longevity crisis, the battle over who owns the relationship with patients, the macro economy and its impact on investments and dealmaking, and more. And we’ll feature panels with top executives and leaders from the FTC and FDA, Biogen, GSK, Goldman Sachs, Ro, and Eikon.
In addition, we have keynotes with some of the most important names in the industry right now:
- I’ll be sitting down one-on-one with the Federal Trade Commission’s Deputy Director of the Bureau of Competition Rahul Rao to ask him about how the FTC sees the biopharma sector, how it’s thinking about M&A, how big is too big, and more.
- Our senior correspondent Andrew Dunn will interview FDA Associate Director for Policy Analysis Tala Fakhouri about the agency’s perspective on AI in drug R&D. There’s been a ton of coverage about how drugmakers are using AI, but far less on how the agency is using it and thinking about it. And no journalist is covering the issue as closely as Andy.
- Biogen CEO Chris Viehbacher and I are going to talk about the new direction he’s setting since taking over at the end of 2022. Biogen is in the middle of a pivotal commercial launch of an Alzheimer’s drug co-developed with Eisai, and we’ll discuss how big biotech is changing and where he’s taking the company.
- ICON CEO Steve Cutler will be interviewed by Financial Times Science Editor Michael Peel, talking about the outlook for the sector and how clinical research is changing.
There are a few tickets left, and Endpoints Insider and Enterprise subscribers get 20% off with the discount code ENDPOINTS20. You can also register to watch online.
If you’re joining us, please say hello to me or any of the Endpoints journalists and staff. We love meeting our readers and we’re always happy to chat between sessions.
See you there!
-Drew